v3.25.2
Segment Reporting and Disaggregation of Relevant Expense Captions (Tables)
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table presents information about reported significant segment expenses and net (loss) income (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Revenues$— $— $— $40,560 
Less:
Research and development (1):
Azenosertib external development costs10,945 25,897 20,551 47,616 
Unallocated research and development expenses and discontinued programs16,665 22,489 34,306 50,355 
Total research and development27,610 48,386 54,857 97,971 
General and administrative 8,448 16,762 19,028 32,502 
Other (2)
9,184 (23,129)(1,268)11,676 
Net loss
$(26,874)$(88,277)$(75,153)$(78,237)
Adjustments for cash used in operations:
Non-cash expenses494 39,811 14,383 (6,670)
Changes in working capital(8,328)13,327 (6,574)(2,206)
Cash used in operations:$(34,708)$(35,139)$(67,344)$(87,113)

(1) The Company tracks external development costs by product candidate or development program, but does not allocate personnel costs, general license payments made under our licensing arrangements or other internal costs to specific development programs or product candidates. These costs are included in unallocated research and development expenses and discontinued programs.
(2) Other consists of investment and other income (expense), restructuring charges and income tax expense.